Featured Jobs
|
BPAS
|
|
Retirement Plan Administration Consultant Blue Ridge Associates
|
|
Relationship Manager for Defined Benefit/Cash Balance Plans Daybright Financial
|
|
Cash Balance/ Defined Benefit Plan Administrator Steidle Pension Solutions, LLC
|
|
MAP Retirement
|
|
BPAS
|
|
July Business Services
|
|
Regional Vice President, Sales MAP Retirement USA LLC
|
|
Pentegra
|
|
Managing Director - Operations, Benefits Daybright Financial
|
|
BPAS
|
|
ESOP Administration Consultant Blue Ridge Associates
|
|
Retirement Plan Consultants
|
|
Southern Pension Services
|
|
Anchor 3(16) Fiduciary Solutions
|
|
Retirement Relationship Manager MAP Retirement
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing
ProPublica 
Feb. 12, 2025 "The story of Zolgensma lays bare a confounding reality about modern drug development, in which revolutionary new treatments are becoming available only to be priced out of reach for many. It's a story that upends commonly held conceptions that high drug prices reflect huge industry investments in innovation. Most of all, it's a story that prompts, again and again, an increasingly urgent question: Do medical advances really have to be this expensive?" MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |